EQS-News: Immunic, Inc.: Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

Issuer: Immunic, Inc. / Key word(s): Study results Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human

Related Keywords

Australia ,New Zealand ,Russia ,Ukraine ,Edna Kaplan ,Paula Schwartz ,Jessica Breu ,Daiichi Sankyo ,Andreas Muehler ,Daniel Vitt ,Exchange Commission ,Daiichi Sankyo Co Ltd ,Rx Communications Group ,Nasdaq ,Immunic Inc ,Distribution Services ,Announces Positive Results ,Multiple Ascending Dose Parts ,Its Phase ,Healthy Human Subjects ,Healthy Human ,Data Revealed ,Favorable Safety ,Pharmacokinetic Profile ,Day Multiple Dosing ,Maximum Tolerated Dose Reached ,Investigated Doses Expected ,Exceed Required Therapeutic Dosing ,Celiac Disease Ongoing ,Held Today ,Investigational Medicinal Product ,Chief Medical Officer ,Chief Executive Officer ,Eastern Time ,Private Securities Litigation Reform Act ,Annual Report ,Investor Relations ,Corporate News ,Regulatory Announcements ,News ,Immunic ,Nnounces ,Positive ,Results ,Rom ,Single ,Multiple ,Ascending ,Nose ,Parts ,Hase ,Linical ,Trial ,Healthy ,Human ,Subjects ,